<DOC>
	<DOCNO>NCT00797732</DOCNO>
	<brief_summary>This study pilot randomize , sham-controlled trial acupuncture Head Neck Cancer ( HNC ) patient dysphagia chemoradiation therapy ( CRT ) . The following hypothesis evaluate : Aim 1 . HNC patient willing eligible participate clinical trial acupuncture , adherent protocol acupuncture baseline follow-up outcome test . Aim 2 . At 20 week post CRT 6 month follow acupuncture treatment : ) MDADI total score sub-scores higher active acupuncture vs. sham control ; b ) time-to-removal feed tube shorter active acupuncture vs. sham control ; c ) body weight recovery increase faster active acupuncture vs. sham control . Aim 3 . At 20 week post CRT , plasma Transforming Growth Factor ( TGF ) -β1 level measure patient treated acupuncture demonstrate trend decrease level compare group similar patient treat sham acupuncture .</brief_summary>
	<brief_title>A Pilot Study Acupuncture Treatment Dysphagia</brief_title>
	<detailed_description>AIMS : Aim 1 . To assess feasibility recruit retain HNC patient dysphagia randomize sham-controlled trial acupuncture . Aim 2 . To collect preliminary data efficacy acupuncture change score HRQOL post CRT head neck cancer patient . Aim 3 . In subset HNC subject treat active sham acupuncture , collect objective measure swallow function use Videofluoroscopic swallow study ( VFSS ) ; salivary flow production ; plasma Transforming Growth Factor ( TGF ) -β1 , Interleukin 6 ( IL-6 ) , Tumor necrosis factor-alpha ( TNF-α ) Interleukin 13 level .</detailed_description>
	<mesh_term>Deglutition Disorders</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>Histologically cytologically proven squamous cell carcinoma head neck ( SCCHN ) stage II , III IV , without evidence distant metastasis . Stage I disease also permit patient receive CRT ; Primary tumor sit eligible : nasopharyngeal , oropharynx , hypopharynx larynx . Tumors nasal paranasal cavity also include . Unknown primary squamous cell carcinoma ( SCC ) neck also eligible . SCC oral cavity also eligible approval treat staff ; Receiving chemoradiation ; Currently recently undergo swallow therapy program without feed tube use , without neck dissection ; Age ≥ 18 year ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Adequate hematological function : neutrophil count &gt; 1.0 x109/L , platelet count &gt; 50x109/L Signed inform consent . Exclusion Criteria Patients follow criterion NOT eligible study : Unstable cardiac disease myocardial infarction within 6 month prior study entry ; Wearing pacemaker implantable cardioverterdefibrillator ; History significant neurologic disorder affect swallow , include stroke , neurodegenerative disease , advance dementia , uncontrolled seizure disorder ; Active clinically significant uncontrolled infection ; Prior use acupuncture dysphagia ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acupuncture</keyword>
	<keyword>dysphagia</keyword>
	<keyword>chemoradiation relate effect</keyword>
	<keyword>squamous cell carcinoma head neck</keyword>
	<keyword>nasopharyngeal cancer</keyword>
	<keyword>oropharynx cancer</keyword>
	<keyword>hypopharynx cancer</keyword>
	<keyword>larynx cancer</keyword>
</DOC>